Navigation Links
American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
Date:2/26/2010

Study highlights:

-- The antiplatelet drug cilostazol was better than aspirin in preventing a recurrent stroke in a Japanese trial.

-- Compared to patients taking aspirin, patients taking the drug were less likely to have new ischemic stroke or develop bleeding requiring hospitalization.

-- Cilostazol is used to reduce leg pain associated with peripheral vascular disease in the United States.

SAN ANTONIO, Feb. 26 /PRNewswire-USNewswire/ -- The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at  preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100222/AHSALOGO)

"This study demonstrated for the first time that cilostazol significantly reduces the risk of recurrent ischemic [blood-clot caused] stroke and the incidence of serious cerebral hemorrhage, compared to aspirin," said Yukito Shinohara, M.D., lead author of the study and head of neurology at Tachikawa Hospital in Tokyo, Japan.

Antiplatelet drugs interfere with the blood's ability to clot.

In the randomized, double-blind study of nearly 2,700 stroke patients with non-cardioembolic ischemic stroke (stroke not caused by blood clots originating in the heart), those treated with cilostazol were 25.7 percent less likely to suffer a stroke than those who received aspirin.

Among the study's other findings:

  • Strokes occurred in 82 of the 1,337 cilostazol-treated patients (two strokes were fatal), during 2,965.9 person-years.  The 1,335-patient aspirin group suffered 119 strokes, including three deaths, over 3,203.6 person-years.  Person-years is the total time all patients in a group received their assigned drug.
  • A hemorrhagic stroke or hemorrhage that required hospitalization occurred in 23 patients taking cilostazol and 57 of those receiving aspirin — a significant difference.

"The primary implication of this trial is that the risk of recurrence of stroke in patients can be reduced without increasing the incidence of hemorrhage by oral administration of cilostazol," Shinohara said.  

Cilostazol is approved in the United States only for reducing intermittent claudication, pain caused by an inadequate flow of blood to the leg muscles that's common with peripheral vascular disease.  In Japan, the drug is recommended and widely used for preventing recurrence of ischemic stroke.

Shinohara and colleagues sought to determine whether cilostazol's preventive powers were in the same range as — or superior to — the effects of aspirin.

The researchers analyzed results from 2,681 ischemic stroke patients treated in 278 Japanese institutions between December 2003 and October 2006.  Patients were followed through 2008. All patients had suffered non-cardioembolic ischemic stroke within 26 weeks prior to enrollment and their symptoms had remained stable.  They were randomized to receive either 100 mg of cilostazol twice daily or 81 mg of aspirin once daily.

"During the trial, we noted that the incidence of recurrent stroke was very low," Shinohara said. "We did not expect that there would be differences between the recurrence rate of stroke in the cilostazol and aspirin groups."

Co-authors are Takenori Yamaguchi, M.D.; Yasuo Katayama, M.D.; Shinichiro Uchiyama, M.D.; Katsuya Nishimaru, M.D.; Yasuhisa Kitagawa, M.D.; Hideo Kusuoka, M.D.; Chokoh Genka, M.D., ; Motoo Tsushima, M.D.; Hiroko Yamamoto, M.D.; Norio Tanahashi, M.D.; Shunnosuke Handa, M.D.; Kempei Matsuoka, M.D.; Yasuo Ohashi, Ph.D.; Yukihiro Koretsune, M.D.; Tohru Sawada, M.D.; and Chikuma Hamada, Ph.D.

Author disclosures are on the abstract.

Otsuka Pharmaceutical Co., Ltd, the maker of cilostazol, funded the study.

Click here to view the video interview with Yukito Shinohara, M.D.

Statements and conclusions of study authors that are presented at American Heart Association/American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing science content.  Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

Note: Actual presentation time is noon CT.

SOURCE American Stroke Association

Back to top
'/>"/>
SOURCE American Stroke Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Heart Association/American College of Cardiology Joint Science Advisory: AHA/ACC Issue Advisory on Diabetes Drugs and Heart Risk
2. Americans Living Longer, Healthier Lives Due to Medical Innovation and New Therapies
3. Many Americans Enjoying Longer, Healthier Lives Due to Medical Innovation and New Therapies
4. American Heart Association Rapid Access Journal Report: Implanted Monitor Accurately Detects Heart Rhythm Disturbances
5. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today
6. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Michigan Today
7. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Massachusetts Today
8. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in North Carolina Today
9. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Missouri Today
10. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Pennsylvania Today
11. The American Academy of Pain Medicine Announces this Years Presidential Commendations and Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> Research and ...
(Date:2/4/2016)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, announced today that it has ... Morgan Stanley & Co. LLC to repurchase $325 million ... the Company,s previously authorized program to repurchase up to ... --> --> Under the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):